Brief: Tiziana Life Sciences Announces Completion Of Prerequisite Pre-Clinical Safety Study
15/12/2022 14:06
Dec 15 (Reuters) - Tiziana Life Sciences Ltd TLSA.O :
* TIZIANA LIFE SCIENCES ANNOUNCES COMPLETION OF PREREQUISITE
PRE-CLINICAL SAFETY STUDY
* TIZIANA LIFE SCIENCES - STUDY SHOWED INTRANASAL FORALUMAB,
ADMINISTERED TO TRANSGENIC MICE AT DOSES UP TO 50 ΜG/RODENT, WAS
CLINICALLY WELL TOLERATED
Source text for Eikon: ID:nGNX4TtsVv
Further company coverage: TLSA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tiziana Life Sciences
See all newsTiziana's experimental MS treatment meets main goals in mid-stage study
Brief: Tiziana Life Sciences - Submits Request To FDA For Orphan Drug Designation For Intranasal Foralumab For Msa
Brief: Tiziana Announces Last Patient Completes Last Visit In Phase 2A Inform-MS Trial Of Intranasal Foralumab
Brief: Tiziana Announces Last Patient Successfully Dosed In Its Phase 2 Inform-MS Trial
Brief: Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis